Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IGC
stocks logo

IGC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
316.50K
+23.15%
-0.020
-0%
373.50K
+13.18%
-0.020
+100%
361.00K
+10.06%
-0.020
-0%
Estimates Revision
The market is revising Downward the revenue expectations for IGC Pharma, Inc. (IGC) for FY2026, with the revenue forecasts being adjusted by -6.57% over the past three months. During the same period, the stock price has changed by -29.42%.
Revenue Estimates for FY2026
Revise Downward
down Image
-6.57%
In Past 3 Month
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-29.42%
In Past 3 Month
Wall Street analysts forecast IGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGC is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGC is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.306
sliders
Low
4.50
Averages
4.50
High
4.50
Current: 0.306
sliders
Low
4.50
Averages
4.50
High
4.50
Alliance Global Partners
James Molloy
Strong Buy
Reiterates
$3.5
2025-03-06
Reason
Alliance Global Partners
James Molloy
Price Target
$3.5
2025-03-06
Reiterates
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$4 → $4.25
2025-02-24
Reason
Ascendiant Capital
Edward Woo
Price Target
$4 → $4.25
2025-02-24
Maintains
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$3.75 → $4
2024-12-05
Reason
Ascendiant Capital
Edward Woo
Price Target
$3.75 → $4
2024-12-05
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for IGC Pharma Inc (IGC.A) is -3.83, compared to its 5-year average forward P/E of -1.56. For a more detailed relative valuation and DCF analysis to assess IGC Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.56
Current PE
-3.83
Overvalued PE
0.11
Undervalued PE
-3.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.86
Current PS
0.00
Overvalued PS
22.06
Undervalued PS
-0.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IGC News & Events

Events Timeline

(ET)
2025-12-02
09:10:00
IGC Pharma Publishes Caregiver-Focused Alzheimer's Book
select
2025-11-25 (ET)
2025-11-25
09:17:09
IGC Pharma Utilizes MINT-AD to Uncover Risk Factors for Alzheimer's Disease
select
2025-11-17 (ET)
2025-11-17
08:45:32
IGC Pharma Anticipates Ongoing Robust Growth in the Second Half of 2026
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-15NASDAQ.COM
Earnings Report Ahead of Market Opening for November 17, 2025: HTHT, ARMK, YMM, JJSF, JKS, CRGO, ARBE, NRXP, IGC, VRME

  • Earnings Reports Overview: Several companies, including H World Group Limited, Aramark, and Full Truck Alliance Co. Ltd., are set to report earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.

  • H World Group Limited (HTHT): Expected earnings per share (EPS) of $0.60, a 3.45% increase year-over-year, with a Price to Earnings (P/E) ratio of 23.31.

  • Aramark (ARMK): Forecasted EPS of $0.65, a 20.37% increase from last year, and a P/E ratio of 20.28, indicating stronger growth compared to industry peers.

  • Negative Earnings Forecasts: Companies like JinkoSolar Holding Company Limited and Freightos Limited are projected to report significant decreases in EPS, with JinkoSolar expected to have a P/E ratio of -2.49, reflecting ongoing challenges.

[object Object]
Preview
9.5
11-15NASDAQ.COM
IGC Pharma, Inc. (IGC) Announces Q2 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: IGC Pharma, Inc. reported a quarterly loss of $0.02 per share, matching the Zacks Consensus Estimate, and revenues of $0.19 million, which fell short of expectations by 56.59%.

  • Earnings Outlook: The company's earnings outlook is mixed, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market, while future earnings estimates remain uncertain.

  • Industry Context: The Medical - Drugs industry, where IGC operates, ranks in the top 34% of Zacks industries, suggesting that industry performance could significantly influence IGC's stock movement.

  • Comparative Analysis: MediWound, a competitor in the same industry, is set to report its quarterly results soon, with expectations of a loss and increased revenues, highlighting the competitive landscape IGC is navigating.

[object Object]
Preview
4.0
10-24NASDAQ.COM
Essential Information on IGC Pharma, Inc. (IGC) Following Rating Upgrade to Strong Buy

  • Zacks Rank Upgrade: IGC Pharma, Inc. has received a Zacks Rank #1 (Strong Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for IGC has risen by 27.3% over the past three months, reflecting analysts' growing confidence in the company's future earnings potential.

  • Investment Strategy: The Zacks rating system, which maintains a balanced approach to stock ratings, positions IGC in the top 5% of stocks based on earnings estimate revisions, suggesting it could outperform the market.

  • Market Potential: IGC Pharma is well-positioned to capitalize on the booming semiconductor market, projected to grow significantly, driven by demand in Artificial Intelligence, Machine Learning, and the Internet of Things.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IGC Pharma Inc (IGC) stock price today?

The current price of IGC is 0.3061 USD — it has increased 1.32 % in the last trading day.

arrow icon

What is IGC Pharma Inc (IGC)'s business?

IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

arrow icon

What is the price predicton of IGC Stock?

Wall Street analysts forecast IGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGC is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IGC Pharma Inc (IGC)'s revenue for the last quarter?

IGC Pharma Inc revenue for the last quarter amounts to 191.00K USD, decreased -53.64 % YoY.

arrow icon

What is IGC Pharma Inc (IGC)'s earnings per share (EPS) for the last quarter?

IGC Pharma Inc. EPS for the last quarter amounts to -0.02 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for IGC Pharma Inc (IGC)'s fundamentals?

The market is revising Downward the revenue expectations for IGC Pharma, Inc. (IGC) for FY2026, with the revenue forecasts being adjusted by -6.57% over the past three months. During the same period, the stock price has changed by -29.42%.
arrow icon

How many employees does IGC Pharma Inc (IGC). have?

IGC Pharma Inc (IGC) has 70 emplpoyees as of December 05 2025.

arrow icon

What is IGC Pharma Inc (IGC) market cap?

Today IGC has the market capitalization of 28.43M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free